|
75
|
266
|
4ueuA |
Tyrosine kinase as - a common ancestor of src and abl |
|
88
|
295
|
4u40A |
Mitogen-activated protein kinase kinase kinase kinase 4 (map4k4) bound to amppnp |
|
111
|
351
|
4s32A |
Crystal structure of erk2 amp-pnp complex |
|
173
|
529
|
4tndA |
Crystal structure of g protein-coupled receptor kinase 5 in complex with amp-pnp |
|
90
|
352
|
4rt7A |
Crystal structure of flt3 with a small molecule inhibitor |
|
91
|
298
|
4twoA |
Human epha3 kinase domain in complex with compound 164 |
|
78
|
277
|
4trlA |
Structure of ephrin type-a receptor 2 |
|
123
|
403
|
4u6rA |
Crystal structure of human ire1 cytoplasmic domains in complex with a sulfonamide inhibitor. |
|
93
|
300
|
4u45A |
Map4k4 in complex with inhibitor (compound 25) |
|
175
|
529
|
4tnbA |
Crystal structure of g protein-coupled receptor kinase 5 in complex with sangivamycin |
|
127
|
419
|
4ualA |
Mrck beta in complex with bdp00005290 |
|
85
|
271
|
4rvkA |
Chk1 kinase domain with diazacarbazole compound 8: n-[3-(6-cyano-9h-pyrrolo[2,3-b:5,4-c']dipyridin-3-yl)phenyl]acetamide |
|
88
|
299
|
4u44A |
Map4k4 in complex with inhibitor (compound 16) |
|
158
|
466
|
4tzrA |
Calcium-dependent protein kinase 1 from toxoplasma gondii (tgcdpk1) in complex with inhibitor uw1561 |
|
82
|
308
|
4rwkA |
Crystal structure of v561m fgfr1 gatekeeper mutation (c488a, c584s, v561m) in complex with n-{3-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-5-yl}-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide (azd4547) |
|
82
|
296
|
4rvtA |
Map4k4 in complex with a pyridin-2(1h)-one derivative |
|
80
|
302
|
4tptA |
Crystal structure of the human limk2 kinase domain in complex with a non-atp competitive inhibitor |
|
112
|
352
|
4s33A |
Erk2 r65s mutant complexed with amp-pnp |
|
100
|
311
|
4u0iA |
Crystal structure of kit in complex with ponatinib |
|
87
|
271
|
4rssA |
Crystal structure of tyrosine-protein kinase syk with an inhibitor |
|
86
|
293
|
4u9aA |
Sulphur anomalous crystal structure of asymmetric irak4 dimer |
|
88
|
323
|
4rj5A |
Egfr kinase (t790m/l858r) with inhibitor compound 5 |
|
66
|
297
|
4qebA |
Dcps in complex with covalent inhibitor targeting tyrosine |
|
95
|
294
|
4rmzA |
Crystal structure of irak-4 |
|
110
|
345
|
4qp9A |
Crystal structure of erk2 in complex with 7-(1-propyl-1h-pyrazol-4-yl)-2-(pyridin-4-yl)-5h-pyrrolo[2,3-b]pyrazine |
|
94
|
322
|
4rj8A |
Egfr kinase (t790m/l858r) with inhibitor compound 8 |
|
78
|
271
|
4qyhA |
Chk1 kinase domain in complex with diazacarbazole gne-783 |
|
76
|
297
|
4riyB |
Crystal structure of an egfr/her3 kinase domain heterodimer containing the cancer-associated her3-e909g mutation |
|
77
|
297
|
4rixB |
Crystal structure of an egfr/her3 kinase domain heterodimer containing the cancer-associated her3-q790r mutation |
|
123
|
358
|
4qtdA |
Structure of human jnk1 in complex with sch772984 and the amppnp-hydrolysed triphosphate revealing the second type-i binding mode |
|
79
|
273
|
4rc2A |
Crystal structure of ser/thr kinase pim1 in complex with mitoxantrone derivatives |
|
145
|
478
|
4qoxA |
Crystal structure of cdpk4 from plasmodium falciparum, pf3d7_0717500 |
|
100
|
326
|
4r7hA |
Crystal structure of fms kinase domain with a small molecular inhibitor, plx3397 |
|
88
|
308
|
4qqcA |
Crystal structure of fgf receptor (fgfr) 4 kinase domain in complex with fiin-2, an irreversible tyrosine kinase inhibitor capable of overcoming fgfr kinase gate-keeper mutations |
|
95
|
302
|
4r7iA |
Crystal structure of fms kinase domain with a small molecular inhibitor, gleevec |
|
108
|
345
|
4qp4A |
Crystal structure of erk2 in complex with n-cyclohexyl-9h-purin-6-amine |
|
71
|
281
|
4rixA |
Crystal structure of an egfr/her3 kinase domain heterodimer containing the cancer-associated her3-q790r mutation |
|
91
|
322
|
4rj4A |
Egfr kinase (t790m/l858r) with inhibitor compound 6 |
|
97
|
285
|
4qmtA |
Mst3 in complex with hesperadin |
|
89
|
263
|
4rg0A |
Crystal structure of btk kinase domain complexed with 2-[8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(4-methylpiperazin-1-yl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-1-oxo-3,4-dihydroisoquinolin-6-yl]-2-methyl-propanenitrile |
|
95
|
334
|
4ra5A |
Human protein kinase c theta in complex with ligand compound 11a (6-[(1,3-dimethyl-azetidin-3-yl)-methyl-amino]-4(r)-methyl-7-phenyl-2,10-dihydro-9-oxa-1,2,4a-triaza-phenanthren-3-one) |
|
81
|
284
|
4rrvA |
Crystal structure of pdk1 in complex with atp and piftide |
|
69
|
281
|
4riyA |
Crystal structure of an egfr/her3 kinase domain heterodimer containing the cancer-associated her3-e909g mutation |
|
82
|
278
|
4qyfA |
Chk1 kinase domain in complex with aminopyrazine compound 13 |
|
70
|
281
|
4riwA |
Crystal structure of an egfr/her3 kinase domain heterodimer |
|
88
|
284
|
4qmsA |
Mst3 in complex with dasatinib |
|
71
|
297
|
4qdvA |
Dcps in complex with covalent ligand |
|
94
|
263
|
4rfzA |
Crystal structure of btk kinase domain complexed with 6-(dimethylamino)-8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]isoquinolin-1-one |
|
90
|
297
|
4qrcA |
Crystal structure of the tyrosine kinase domain of fgf receptor 4 in complex with ponatinib |
|
103
|
287
|
4r78A |
Crystal structure of lica in complex with amp |
